Literature DB >> 23288426

Evidence of ongoing replication in a human immunodeficiency virus type 1 persistently infected cell line.

Isabel Olivares1, Carmen Sánchez-Jiménez1, Catarina Reis Vieira1, Víctor Toledano1, Mónica Gutiérrez-Rivas1, Cecilio López-Galíndez1.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) persistently infected cell lines are characterized by the continuous viral production without cytopathic effect. However, it is not completely clear if this production is contributed only by viral transcription or also by new cycles of viral replication. We studied an HIV-1 persistently infected cell line, designated H61-D, providing evidence of new replication cycles as sustained by: (i) a decrease in viral production, measured by p24 protein, after treatment of the culture with 3'-azydo-3'-deoxythymydine; (ii) detection of new integration events in the course of cell culture, and (iii) finding of two-long-terminal repeat circles in the cells. H61-D cells were not infected by cell-free virus, but infection was possible by co-culture with another productive-infected cell line. In conclusion, ongoing viral replication is taking place in H61-D persistent cells and new infections are mediated by a cell-to-cell spread mechanism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288426     DOI: 10.1099/vir.0.046573-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  2 in total

Review 1.  Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update.

Authors:  Faysal Bin Hamid; Jinsun Kim; Cha-Gyun Shin
Journal:  AIDS Res Ther       Date:  2017-02-16       Impact factor: 2.250

2.  HIV integration sites in latently infected cell lines: evidence of ongoing replication.

Authors:  Jori Symons; Abha Chopra; Eva Malatinkova; Ward De Spiegelaere; Shay Leary; Don Cooper; Chike O Abana; Ajantha Rhodes; Simin D Rezaei; Linos Vandekerckhove; Simon Mallal; Sharon R Lewin; Paul U Cameron
Journal:  Retrovirology       Date:  2017-01-13       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.